[HTML][HTML] A comprehensive meta-analysis of transcriptome data to identify signature genes associated with pancreatic ductal adenocarcinoma
SO Kordshouli, A Tahmasebi, A Moghadam… - Plos one, 2024 - journals.plos.org
Purpose Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of less than
5%. Absence of symptoms at primary tumor stages, as well as high aggressiveness of the …
5%. Absence of symptoms at primary tumor stages, as well as high aggressiveness of the …
A comprehensive meta-analysis of transcriptome data to identify signature genes associated with pancreatic ductal adenocarcinoma.
SO Kordshouli, A Tahmasebi, A Moghadam… - PLoS …, 2024 - search.ebscohost.com
Purpose: Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of less
than 5%. Absence of symptoms at primary tumor stages, as well as high aggressiveness of …
than 5%. Absence of symptoms at primary tumor stages, as well as high aggressiveness of …
A comprehensive meta-analysis of transcriptome data to identify signature genes associated with pancreatic ductal adenocarcinoma.
SO Kordshouli, A Tahmasebi, A Moghadam… - PLoS ONE, 2024 - go.gale.com
Purpose Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of less than
5%. Absence of symptoms at primary tumor stages, as well as high aggressiveness of the …
5%. Absence of symptoms at primary tumor stages, as well as high aggressiveness of the …
A comprehensive meta-analysis of transcriptome data to identify signature genes associated with pancreatic ductal adenocarcinoma
SO Kordshouli, A Tahmasebi, A Moghadam… - PloS …, 2024 - pubmed.ncbi.nlm.nih.gov
Purpose Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of less than
5%. Absence of symptoms at primary tumor stages, as well as high aggressiveness of the …
5%. Absence of symptoms at primary tumor stages, as well as high aggressiveness of the …
[HTML][HTML] A comprehensive meta-analysis of transcriptome data to identify signature genes associated with pancreatic ductal adenocarcinoma
SO Kordshouli, A Tahmasebi, A Moghadam… - PLOS …, 2024 - ncbi.nlm.nih.gov
Purpose Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of less than
5%. Absence of symptoms at primary tumor stages, as well as high aggressiveness of the …
5%. Absence of symptoms at primary tumor stages, as well as high aggressiveness of the …
A comprehensive meta-analysis of transcriptome data to identify signature genes associated with pancreatic ductal adenocarcinoma
S Kordshouli, A Tahmasebi, A Moghadam, A Ramezani… - Plos one, 2024 - europepmc.org
Purpose Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of less than
5%. Absence of symptoms at primary tumor stages, as well as high aggressiveness of the …
5%. Absence of symptoms at primary tumor stages, as well as high aggressiveness of the …
A comprehensive meta-analysis of transcriptome data to identify signature genes associated with pancreatic ductal adenocarcinoma
SO Kordshouli, A Tahmasebi, A Moghadam… - PLoS …, 2024 - ui.adsabs.harvard.edu
Purpose Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of less than
5%. Absence of symptoms at primary tumor stages, as well as high aggressiveness of the …
5%. Absence of symptoms at primary tumor stages, as well as high aggressiveness of the …
A comprehensive meta-analysis of transcriptome data to identify signature genes associated with pancreatic ductal adenocarcinoma.
SO Kordshouli, A Tahmasebi, A Moghadam… - Plos one, 2024 - europepmc.org
Purpose Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of less than
5%. Absence of symptoms at primary tumor stages, as well as high aggressiveness of the …
5%. Absence of symptoms at primary tumor stages, as well as high aggressiveness of the …